CLBIO Corline Biomedical AB (publ)

1.412USD14.35 SEK · STO+0.35%Mkt Cap: 36.91M USDP/E: —

Corline Biomedical AB (publ) develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are bas…

Key Statistics

Company
Market Cap36.91M USD
Enterprise Value33.97M USD
Revenue (TTM)1.24M USD
Gross Profit612.82K USD
Net Income (TTM)-1.45M USD
Revenue/Share0.05 USD
Last Price1.412 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees12
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0006887451
Valuation
P/E (Trailing)—
P/E (Forward)16.12
PEG—
EV/EBITDA-26.65
EV/Revenue27.33
P/S29.70
P/B3.98
EPS (TTM)-0.05 USD
EPS (Forward)0.09 USD
52W Range
0.964645% of range1.964
52W High1.964 USD
52W Low0.9646 USD
Profitability
Gross Margin81.37%
Oper. Margin-103.62%
EBITDA Margin-102.57%
Profit Margin-192.31%
ROE-15.69%
ROA-14.93%
ROIC—
ROCE-15.73%
Growth
Revenue Growth82.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.74M USD
CapEx (TTM)96.76K USD
FCF Margin-84.80%
FCF Yield-2.86%
Net Debt-2.94M USD
Net Debt/EBITDA2.31
Net Debt/FCF—
Balance Sheet
Debt/Equity4.97
Current Ratio6.52
Quick Ratio6.13
Book Value/Sh0.35 USD
Cash/Share0.11 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.969 USD
Upside (mean)+39.4%
Target Range1.969 USD – 1.969 USD
# Analysts1
Ownership
Shares Out.26.13M
Float11.31M
Insiders62.42%
Institutions12.84%
Technical
SMA 501.392 (+1.5%)
SMA 2001.596 (-11.5%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)21.05K
Avg Vol (10d)31.29K
Technical Indicators
RSI (14)55.9
MACD0.0063
MACD Signal-0.1462
MACD Hist.+0.1526
BB Upper1.472 USD
BB Middle1.360 USD
BB Lower1.249 USD
BB Width16.40%
ATR (14)0.1213 USD
Vol Ratio (20d)0.28x

About Corline Biomedical (STO: CLBIO)

›

Corline Biomedical (STO: CLBIO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 12 employees.

The shares were at 14.35 SEK on 19 November 2026, down 25.3% over 52 weeks. Its 52-week range is 9.800 SEK to 19.95 SEK: the price is 28.1% below the high and 46.4% above the low.

Its market capitalisation is 375.01M SEK.

Corline Biomedical reports return on equity of -15.7%, an operating margin of -103.6% and revenue up 82.9% year over year.

It holds more cash than debt, a net cash position of 29.87M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 20.00 SEK is 39.4% above the current price.